Drugs / Mutant KRAS G12V-specific TCR transduced autologous T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04146298 | Oct 2021 → Jun 2027 expected | pancreatic ductal adenocarcinoma | Changhai Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mutant KRAS G12V-specific TCR transduced autologous T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04146298 ↗ |
| Action | Deplete | “mutant KRAS antigen-specific TCR transduced autologous Tcells will target and kill HLA-matched mutant KRAS cancer cells but not normal cells” NCT04146298 ↗ |
| Modality | Cell therapy | “adoptive transfer of autologous T cells genetically engineered to express a TCR” NCT04146298 ↗ |
| Route | Intravenous | “T cells will be infused to the patient intravenously” NCT04146298 ↗ |
| Target | KRAS | “a TCR that targets mutant KRAS G12V” NCT04146298 ↗ |